For years investigators have observed that an increasing share of lung cancer diagnoses occur among people who report never having smoked. Researchers have sought to identify factors—genetic, environmental, or otherwise—that might explain elevated risk in this group. The source article frames the new study as part of that effort, aiming to determine whether distinct, non–tobacco-related contributors can be identified and linked to tumor risk and ultimately inform screening and treatment approaches.
The study reported in the journal Science identified a rare genetic variant that the authors associate with substantially higher odds of lung cancer. The source states that carriers of the variant had about 25-fold higher odds of lung cancer. Experts quoted in the account emphasize that, despite the large relative effect size, the variant is very rare and therefore is likely to explain only a small number of lung cancer cases among people who have never smoked.
According to the source, the variant is considerably more common among people living in Southern Appalachia compared with other regions of the United States. The article highlights the regional enrichment as a notable epidemiologic observation from the study, suggesting geographic clustering of a rare inherited risk factor.
The investigators relied on genetic data collected by 23andMe to perform their analyses. The source frames the finding as an example of how very large datasets that combine genetic and health information from millions of people can enable detection of narrow but important signals—such as rare variants with large effect sizes—that smaller studies would miss. Beyond noting the use of the 23andMe dataset, the excerpt does not report specific analytic methods, sample sizes, or replication details.
Experts in the piece caution that the newly identified variant probably accounts for only a small proportion of lung cancer in never-smokers, so it does not explain the broader trend of rising never-smoker lung cancer prevalence. Nevertheless, the study contributes to the accumulating evidence that some never-smoker lung cancers have distinct risk factors compared with smoking-associated tumors. The source suggests these distinctions could influence thinking about screening and treatment strategies for subsets of patients, and underscores the value of genomic information in refining risk stratification and research priorities.
The published excerpt provides several headline findings but leaves many scientific and clinical details unreported. The source does not provide the variant’s specific genetic identity or locus, carrier frequency in the populations studied, absolute risk estimates, the number of cases or controls analyzed, statistical methods, functional or mechanistic data linking the variant to tumor biology, or recommendations for clinical action. It also does not report whether the finding has been independently replicated or whether there are implications for genetic screening in affected regions. Those omissions are explicitly noted in the article.
A Science paper described in the source identifies a very rare variant associated with large relative increases in lung cancer odds among carriers, and the variant appears more frequent in Southern Appalachia. The finding illustrates how large consumer-genetics datasets like 23andMe can uncover rare but meaningful risk factors, but it likely explains only a small slice of never-smoker lung cancers. The source stresses that additional details and follow-up—many of which were not reported in the excerpt—are needed before any changes to clinical practice are warranted.
(Article by Andrew Joseph, Sept. 17, 2026, as summarized in the source. The source excerpt did not include further study-specific data or clinical recommendations.)